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Abstract
Background The increased use of neoadjuvant chemo-
therapy and minimally invasive therapies for recurrence in
patients with colorectal liver metastases (CLM) makes a
surgical strategy to save as much liver volume as possible
pivotal. In this study, we determined the difference in
morbidity and mortality and the patterns of recurrence and
survival in patients with CLM treated with anatomical
(AR) and nonanatomical liver resection (NAR).
Methods From January 2000 to June 2008, patients with
CLM who underwent a resection were included and divi-
ded into two groups: patients who underwent AR, and
patients who underwent NAR. Patients who underwent
simultaneous radiofrequency ablation in addition to sur-
gery and patients with extrahepatic metastasis were
excluded. Patient, tumor, and treatment data, as well as
disease-free and overall survival (OS) were compared.
Results Eighty-eight patients (44%) received AR and 113
patients (56%) underwent NAR. NAR were performed for
signiﬁcant smaller metastases (3 vs. 4 cm, P\0.001). The
Clinical Risk Score did not differ between the groups. After
NAR, patients received signiﬁcantly less blood transfu-
sions (20% vs. 36%, P = 0.012), and the hospital stay
was signiﬁcantly shorter (7 vs. 8 days, P\0.001). There
were no signiﬁcant differences in complications, positive
resection margins, or recurrence. For the total study group,
estimated 5-year disease-free and OS was 31 and 44%,
respectively, with no difference between the groups.
Conclusions Our study resulted in no signiﬁcant differ-
ence in morbidity, mortality, recurrence rate, or survival
according to resection type. NAR can be used as a save
procedure to preserve liver parenchyma.
Introduction
Colorectal cancer is the most common gastrointestinal
malignancy worldwide, affecting nearly one million people
each year [1]. Half of these patients have or will develop
hepatic metastases at some point during their life. Liver
resection is considered to be the best treatment for colo-
rectal liver metastases (CLM) with 5-year survival rates up
to 60% in highly selected patients [2]. Until recently, only
10–20% of patients were considered suitable for attempted
curative resection [3, 4]. Due to improvements in surgical
techniques, the acceptance of resection margins\1 cm, the
introduction of more effective systemic chemotherapeutics,
the use of portal vein embolization (VPE), the addition of
radiofrequency ablation (RFA), and stereotactic body
radiation (STBR) to surgery, more patients are eligible for
liver surgery [5–13]. Moreover, the indications for liver
resection have expanded during the past decade and there
are only few limitations left, which include unresectable
extrahepatic disease and insufﬁcient future remnant liver.
The question has shifted from ‘‘what can be resected’’ to
‘‘what will be left.’’
During this period, a change in surgical approach can be
observed by an increase of nonanatomicalresections [14]. A
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liver parenchyma, which is important, in particular for
patients whoreceivedneoadjuvantchemotherapy.Although
chemotherapy increases resectability, it is associated with
hepatic changes, which might increase the risk of progres-
sive hepatic failure and death after resection [15, 16].
Moreover, in case of intrahepatic recurrences after partial
liver resection in patients with CLM, a sufﬁcient liver
residual can offer the opportunity for local treatment [17].
Although anatomical hepatic resection has been reported
to improve patient survival in hepatocellular carcinoma
(HCC) [18–20], the literature about CLM is conﬂicting.
The purpose of this study was to investigate the inﬂu-
ence of a nonanatomical liver resection (NAR) compared
with an anatomical resection (AR) on morbidity, mortality,
margin positivity, disease-free, and OS.
Methods
All patients who underwent partial hepatic resection for
CLM at the Erasmus Medical Center from January 2000 to
June 2008 were evaluated for inclusion in this study.
Patients who underwent simultaneous AR and NAR or
received additional RFA in addition to surgery as well as
patients with extrahepatic metastasis were excluded.
Patients were divided into two groups: patients who
underwent an AR, and patients who underwent a NAR. An
AR was deﬁned as resection of two or more hepatic seg-
ments as described by Couinaud [21]. This includes biseg-
mentectomy,(extended)righthemihepatectomy,(extended)
left hemihepatectomy, or a combination of these [22]. NAR
was deﬁned as resection of the CLM, including a rim of
microscopically normal tissue. The choice of resection type
was made in a multidisciplinary hepatobiliary working
group, based on tumor number, location, and patient status.
Information collected included demographic details,
primary tumor stage (TNM-classiﬁcation), maximum size,
number and distribution of liver metastases on CT, plasma
carcinoembryonic antigen (CEA) levels, neoadjuvant che-
motherapy, Clinical Risk Score (CRS) [23], type of liver
surgery, transfusion data, overall duration of hospital stay,
perioperative complications, radicality, site, and treatment
of recurrence.
Overall survival and disease-free survival (DFS) were
calculated from the date of liver resection. Complications
or death occurring within 30 days or before discharge were
considered perioperative. We deﬁned a positive surgical
margin as the presence of vital tumor along the line of
transection.
After partial hepatic resection, patients routinely
underwent a physical examination and determination of
CEA level, abdominal/chest CT, or ultrasonography every
4 months for the ﬁrst year, every 6 months the second year
and once per year thereafter.
Statistical analyses were conducted using SPSS (version
15, SPSS Inc., Chicago, IL). Categorical variables are
presented as number (percentage). Continuous variables
are presented as median (range). Categorical variables were
compared with the chi-square test; continuous variables
were compared with the Mann-Whitney U test. Actuarial
survival was calculated using the Kaplan-Meier method
from the date of resection of CLM, and differences in
survival were examined using the log-rank test. P\0.05
(two-sided) was considered signiﬁcant.
Results
Clinicopathological variables
Between January 2000 and June 2008, 308 patients
underwent a partial hepatic resection for CLM; 201
patients met the study inclusion criteria, including 126 men
(63%) and 75 women (37%). The median age was 65
(range, 30–86) years. The primary tumor was located in the
colon in 114 patients (57%) and rectum in 87 patients
(43%). After resection of the initial tumor, positive lymph
nodes were present in 114 patients (57%); synchronous
liver metastases were identiﬁed in 78 patients (39%). The
median disease-free interval for the remaining 123 patients
was 20 (range, 4–193) months from the time of resection of
the colorectal tumor. The median CEA level was 16 (range,
1–1,292) ng/ml at the time of liver resection. In 16 patients
(8%), the CEA level exceeded 200 ng/ml. The median
number of metastases was one (range 1–8) with a median
diameter of the largest metastases of 3 (range, 0.5–15) cm.
The CRS was C3 in 60 patients (30%). Fifty-nine patients
(31%) were treated with neoadjuvant chemotherapy. AR
was performed in 88 patients and NAR was performed in
113 patients. The clinicopathological features of the AR
and NAR are compared in Table 1.
Surgical treatment
A single NAR was performed in 69 patients (61%),
whereas 44 (39%) had two or more NAR simultaneously.
A right hemihepatectomy was the most frequently per-
formed AR (47 resections, 43%) followed by left hemi-
hepatectomy (15 resections, 14%). Bisegmentectomies
were performed in 18 patients (21%; Table 2).
Outcome
Table 3 presents the outcome of patients who underwent
AR versus NAR. After AR, 32 patients (36%) received a
World J Surg (2011) 35:656–661 657
123blood transfusion. This was signiﬁcantly lower after a NAR
(23 patients, 20%; P=0.012). The transfused patients in
the AR group received a median of 3 units of erythrocytes
(range 1–6). In the NAR group, the median transfusion rate
also was 3 units of erythrocytes (range 1–9), but with a
larger range. The hospital stay was signiﬁcantly shorter
after NAR (7 (range, 1–26) days vs. 8 (range, 4–42) days;
P\0.001). There was no signiﬁcant difference in mor-
tality rate between the two groups. Insufﬁcient capacity of
the liver remnant was the cause of death in the two patients
in the AR group. One patient in the NAR group died due to
aspiration pneumonia. The median follow-up was 35
(range, 1–111) months in both groups. With respect to the
median time to recurrence, the groups were comparable
(AR group 9 (range, 1–46) months vs. 10 (range, 2–55)
months in the NAR group; P = 0.802). The DFS was
similar for the AR and NAR groups: 56%, 38%, 30%, and
60%, 39%, 32% at 1, 3, and 5 years, respectively
(P = 0.441, P = 0.81, P=0.599; Fig. 1). The pattern of
recurrence did not differ between the two groups (Table 4).
The 3-year intra hepatic recurrence rate was 37% in the AR
group and 33% in the NAR group (P=0.62). Seventeen
patients in the AR group and 26 patients in the NAR group
developed liver metastases limited to the liver. These
patients received similar therapy (Table 4). The OS was
96%, 61%, and 49% for the AR group and 97%, 65%, and
39% for the NAR group at 1, 3, and 5 years, respectively
(P = 0.715, P = 0.611, P = 0.989; Fig. 2).
Discussion
This study demonstrated no signiﬁcant difference in out-
come between patients with CLM after anatomical or
NAR. The 5-year disease-free (AR 30% vs. NAR 32%) and
OSs (AR 49% vs. NAR 39%) in our study is consistent
with the literature [2, 24–28].
Table 1 Clinicopathological variables
Variable Anatomical Nonanatomical P value
(n = 88) (n = 113)
Age (year) 65 (30–82) 65 (36–86) 0.585
Gender (male) 56 (64) 70 (62) 0.806
No. of tumors 2 (1–7) 1 (1–7) 0.295
Size largest tumor (cm)
a 4 (1–15) 3 (1–7) \0.001
Bilobar distribution 20 (23) 32 (28) 0.369
CEA
b 16.4 (1–1292) 15.9 (1–909) 0.078
[200 ng/ml 10 (12) 6 (5) 0.113
Time to resection
Synchronous 35 (40) 43 (38) 0.804
Metachronous 53 (60) 70 (62)
Disease-free interval (mo) 24 (4–93) 17 (4–193) 0.430
Clinical risk score
a
1–2 57 (66) 82 (73) 0.241
3–5 30 (34) 30 (27)
Neoadjuvant chemotherapy 31 (35) 28 (25) 0.107
Site primary tumor
Colon 55 (63) 59 (52) 0.144
Rectum 33 (37) 54 (48)
Tumor stage primary tumor
0–2 12 (14) 23 (20) 0.213
3–4 76 (86) 90 (80)
Lymph node primary tumor
Positive 45 (51) 69 (61) 0.159
Negative 43 (49) 44 (39)
Missings:
a = 2,
b = 4
Data are numbers with percentages in parentheses or medians with
ranges in parentheses unless otherwise indicated
Table 2 Type of resection
Liver resection No. of resections
(N = 201) (%)
Nonanatomical (n = 113)
Single 69 61
Two 25 22
Three 13 12
Four 4 3
Five 2 2
Anatomical (n = 88)
S 2–3 12 14
S 6–7 6 7
Right hemihepatecomy 47 53
Left hemihepatectomy 15 17
Extended right hemihepatectomy 4 5
Extended left hemihepatectomy 1 1
Combination of anatomical resections
a 33
S segment
a seg 2–3 ? seg 1 resection, seg 2–3 ? seg 6–7 resection
Table 3 Outcome surgery
Variable Anatomical Nonanatomical P value
(n = 88) (n = 113)
Blood transfusion 32 (36) 23 (20) 0.012
Hospital stay 8 (4–42) 7 (1–26) \0.001
Complications 24 (27) 26 (23) 0.488
In-hospital mortality 2 (2) 1 (1) 0.421
Positive resection margins 8 (9) 12 (11) 0.728
Data are numbers with percentages in parentheses or medians with
ranges in parentheses unless otherwise indicated
658 World J Surg (2011) 35:656–661
123The major drawback is the retrospective nature of this
study. Randomization would be difﬁcult in this patient
group, because the technique for liver resection is a tailor-
made approach based on the size, number, location, and
distribution of the metastases. In addition, the consider-
ation between conservation of liver parenchyma, com-
plete surgical tumor clearance, and complications is of
importance in this decision. Although patients were not
randomized, the basic characteristics were similar as shown
in Table 1.
Liver parenchymal-sparing surgery is already frequently
used for CLM for several reasons. Functional hepatic
reserve must be considered for any liver resection; its
signiﬁcance increases in the context of neoadjuvant che-
motherapy, which is used to downsize the tumor load,
making more patients eligible for surgery [29]. However,
although chemotherapy increases resectability, it is asso-
ciated with signiﬁcant hepatic changes, such as hepatic
sinusoidal obstruction, periportal inﬂammation, and ste-
atohepatitis, which can affect patient outcome [15]. Spe-
ciﬁcally, chemotherapy-associated steatohepatitis is
associated with the risk of progressive hepatic failure and
death after resection [16]. Therefore, maximizing the
amount of residual liver parenchyma is of considerable
importance in patients who have had chemotherapy.
Moreover, surgical stress can be reduced by nonana-
tomical resections, which may affect perioperative mor-
bidity and mortality [14, 25]. Several studies reported
signiﬁcant shorter operating times and signiﬁcant less blood
loss after NAR [25, 26, 28]. This also is seen in our study
population. Patients who underwent AR received signiﬁcant
more blood transfusions than the patients after NAR (AR
36% vs. NAR 20%; P = 0.012). In our series, there were
three deathswithin 30 daysof surgery: two inthe ARgroup,
and one in the NAR, which was not signiﬁcantly different.
There are studies suggesting more postoperative deaths in
the AR group [2, 25, 26, 28]. It is important to note that
postoperative mortality is a rare event and that these studies
are not powered to compare this.
The possibility to treat recurrent CLM with local ther-
apy, such as repeated hepatectomy [17], RFA [11], or
STBR [30] is a great beneﬁt of the parenchymal sparing
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Fig. 1 Disease-free survival stratiﬁed by surgical procedure. Median
DFS was 16.7 months in the AR group and 18.7 months in the
NAR group. The 5-year DFS rate was 30 and 32%, respectively
(P = 0.599)
Table 4 Patterns of recurrence and treatment modality
Anatomical Nonanatomical P value
(n = 88) (n = 113)
Location recurrence 0.156
Liver 17 (30) 26 (38)
Liver ? lung 10 (18) 4 (6)
Liver ? elsewhere 2 (2) 5 (7)
Elsewhere 28 (49) 34 (49)
Therapy liver metastases 0.398
No therapy 1 (6) 2 (8)
Systemic therapy 9 (53) 8 (32)
Local therapy 7 (41) 15 (60)
Resection 3 10
RFA 2 3
STBR 1 2
Liver perfusion 1 0
RFA radiofrequency ablation; STBR stereotactic body radiation
Data are numbers with percentages in parentheses or unless otherwise
indicated
No. at risk
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Fig. 2 Overall survival stratiﬁed by surgical procedure. Median OS
was 49 months in the AR group and 47.2 months in the NAR group.
The 5-year OS rate was 49 and 39%, respectively (P = 0.989)
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123method. In our study, disease recurrence in the liver was
similar for both AR and NAR (51%). The reintervention
rate for CLM was higher in the NAR group (AR 41% vs.
NAR 60%). Although this number does not reach signiﬁ-
cance, probably due to the small numbers, our ﬁndings
suggest that local treatment for intrahepatic recurrences is
more often possible in the parenchymal-sparing method.
Our ﬁndings are consisted with the literature, which states
that reinterventions for CLM increases the survival after
disease recurrence [31–33]. For this reason, close surveil-
lance of patients after NAR is essential. One of the possi-
ble disadvantages of NAR reported in the literature by
DeMatteo et al. [24] is the higher incidence of positive
resection margins. In more recently published literature, it
is advocated that a resection margin\1 cm is no longer a
contraindication for curative resection. Moreover recent
literature suggests that size of surgical margin does not
correlate signiﬁcantly with DFS or OS; even the need for
R0 resections is being discussed [34, 35]. In a study by de
Haas et al., the 5-year OS was similar for patients after a
R0 or a R1 resection (61 vs. 57%; P = 0.27), although the
recurrence was higher in the R1 group (28 vs. 17%;
P = 0.004) [6]. In our study, the R1 resection rate was 9%
in the AR group and 11% in the NAR group, which is
comparable to the literature [6, 27]. The concept of per-
forming limited NAR with narrow margins is supported by
the fact that micrometastases in the liver parenchyma
surrounding CLM are rare and are primarily conﬁned to the
immediate surrounding area of the tumor border [36, 37].
The second possible drawback of NAR, which is pos-
tulated in the literature ([24]), is the lack of vascular con-
trol. This is the opposite of what was published during the
past years. Blood loss and blood transfusions are reported
to be signiﬁcantly less during and after NAR, which is
conﬁrmed by our results [25, 26, 28].
In contrast to CLM, some studies report AR to be
superior to NAR in HCCs [18–20]. This difference may be
explained by the variation in disease biology seen in pri-
mary versus metastatic liver tumors. Metastatic liver
lesions develop from blood-borne tumor cells circulating
throughout the body. AR may not offer the same advantage
for these lesions as for HCC, which arise within a segment
of the liver and might beneﬁt from the removal of the
complete functional liver unit.
Multiple studies have been conducted to investigate
which resection is favorable for patients with CLM: ana-
tomical or nonanatomical. Most authors similarly conclude
that there is no signiﬁcant difference between AR and NAR
in disease-free and OSs. A disadvantage of the majority of
studies is that the patient characteristics are not comparable
between the two groups regarding tumor size and number,
nodal status of the primary tumor, disease-free interval, and
CEA blood levels [2, 14, 25, 26]. Our study contributes to
this discussion due to the use of the CRS in which the
previous described characteristics are incorporated. The
CRS is the same for the AR and NAR, which indicates that
the groups are comparable.
Furthermore, the use of different neoadjuvant chemo-
therapy regimens during the years makes it difﬁcult to
compare the results of the studies [2, 14, 26–28]. We
started our patient selection after 2000, because Irinotecan
and Oxaliplatin were added to the chemotherapeutic arse-
nal from this year forward, and all patients were treated
with effective chemotherapeutics.
We conclude that with a comparable complication rate,
less blood transfusions, a signiﬁcantly shorter hospital, and
comparable disease-free and OS rates, a NAR is a safe
technique for the resection of CLM.
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